Regulation of intermittent oscillatory activity of pyramidal cell neurons by GABA inhibitory interneurons is impaired in schizophrenia: Rationale for pharmacotherapeutic GABAergic interventions

Israel Journal of Psychiatry and Related Sciences

Volumn 47, Issue 1, 2010, Pages 17-26

  Deutsch, Stephen I ^a   Rosse, Richard B ^b,c   Schwartz, Barbara L ^b,c   Mastropaolo, John ^b   Burket, Jessica A ^a   Weizman, Abraham ^d  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77953191666     PISSN: 03337308     EISSN: 26172402     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Daskalakis ZJ, Fitzgerald PB, Christensen BK. The role of cortical inhibition in the pathophysiology and treatment of schizophrenia. Brain Res Rev 2007; 56: 427-442.
2. Deutsch SI, Rosse RB, Schwartz BL, Mastropaolo J. A revised excitotoxic hypothesis of schizophrenia: Therapeutic implications. Clin Neuropharmacol 2001; 24: 43-49.
3. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007; 27: 11496-11500.
4. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005; 6: 312-324.
5. Lewis DA, Gonzalez-Burgos G. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacol Rev 2008; 33: 141-165.
6. Moghaddam B, Adams B, Verma A, Daly, D. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997; 17: 2921-2927.
7. Deutsch SI, Park CH, Lukacs LG, Morn C, Koetzner L, Mastropaolo J. MK-801 alters the GABAA receptor complex and potentiates flurazepam's antiseizure efficacy. Pharmacology Biochemistry and Behavior 1995; 51: 909-915.
8. Huntsman MM, Tran BV, Potkin SG, Bunney Jr., WE, Jones EG. Altered ratios of alternatively spliced long and short gamma2 subunit mRNAs of the gamma-amino butyrate type A receptor in prefrontal cortex of schizophrenics. Proc Natl Acad Sci USA 1998; 95: 15066-15071.
9. Mohler H. GABAA receptor diversity and pharmacology. Cell Tissue Res 2006; 326: 505-516.
10. Barnard EA, Skolnick P, Olsen RW, Mohler H, Sieghart W, Biggio G, Braestrup C, Bateson AN, Langer SZ. Subtypes of γ-aminobutyric acidA receptors: Classification on the bases of subunit structure and receptor function. Pharmacol Rev 1998; 50: 291-313.
11. Benson J, Low K, Keist R, Mohler H, Rudolph U. Pharmacology of recombinant GABAA receptors rendered diazepam-insensitive by point-mutated α-subunits. FEBS Lett 1998; 431: 400-404.
12. Howard MW, Rizzuto DS, Caplan JB, Madsen JR, Lisman J, Aschenbrenner-Scheibe R, Schulze-Bonhage, A, Kahana, MJ. Gamma oscillations correlate with working memory load in humans. Cereb Cortex 2003; 13: 1369-1374.
13. Menzies L, Ooi C, Kamath S, Suckling J, McKenna P, Fletcher P, Bullmore E, Stephenson C. Effects of γ-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia. Arch Gen Psychiatry 2007; 64: 156-167.
14. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney Jr WE, Jones EG. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 1995; 52: 258-266.
15. Benes FM, Vincent SL, Alsterberg G, Bird ED, SanGiovanni JP. Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics. J Neurosci 1992; 12: 924-929.
16. Hashimoto T, Arion D, Unger T, Maldonado-Aviles JG, Morris HM, Volk DW, Mirnics K, Lewis DA. Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 2008; 13: 147-161.
17. Simpson MDC, Slater P, Deakin JFW, Royston MC, Skan WJ. Reduced GABA uptake sites in the temporal lobe in schizophrenia. Neurosci Lett 1989; 107: 211-215.
18. Simpson MD, Slater P, Royston MC, Deakin JF. Regionally selective deficits in uptake sites for glutamate and gammaaminobutyric acid in the basal ganglia in schizophrenia. Psychiatry Res 1992; 42: 273-282.
19. Guidotti A, Auta J, Davis JM, Dwivedi Y, Gerevini VD, Impagnatiello F, Pandey G, Pesold C, Sharma R, Uzunov DP, Costa E. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: A postmortem brain study. Arch Gen Psychiatry 2000; 57: 1061-1069.
20. Harte MK, Powell SB, Swerdlow NR, Geyer MA, Reynolds GP. Deficits in parvalbumin and calbindin immunoreactive cells in the hippocampus of isolation reared rats. J Neural Transm 2007; 114: 893-898.
21. Guidotti A, Auta J, Davis JM, Dong E, Grayson DR, Veldic M, Zhang X, Costa E. GABAergic dysfunction in schizophrenia: New treatment strategies on the horizon. Psychopharmacology 2005; 180: 191-205.
22. Deutsch SI, Mastropaolo J, Hitri A. GABA-active steroids: Endogenous modulators of GABA-gated chloride ion conductance. Clinical Neuropharmacology 1992; 15: 352-364.
23. Deutsch SI, Rosse RB, Lakshman RM. Dysregulation of tau phosphorylation is a hypothesized point of convergence in the pathogenesis of Alzheimer's disease, frontotemporal dementia and schizophrenia with therapeutic implications. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1369-1380.
24. Grayson DR, Jia X, Chen Y, Sharma RP, Mitchell CP, Guidotti A, Costa E. Reelin promoter hypermethylation in schizophrenia. Proc Natl Acad Sci USA 2005; 102: 9341-9346.
25. Veldic M, Guidotti A, Maloku E, Davis JM, Costa E. In psychosis, cortical interneurons overexpress DNA-methyltransferase 1. Proc Natl Acad Sci USA 2005; 102: 2152-2157.
26. Deutsch SI, Rosse RB, Mastropaolo J, Long KD, Gaskins BL. Epigenetic therapeutic strategies of neuropsychiatric disorders: Ready for prime time? Clin Neuropharmacol 2008; 31: 104-119.
27. Tochigi M, Iwamoto K, Bundo M, Komori A, Sasaki T, Kato N, Kato T. Methylation status of the reelin promoter region in the brain of schizophrenic patients. Biol Psychiatry 2008; 63: 530-533.
28. Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K, Flach K, Nagamoto H, Bickford P, Leonard S, Freedman R. Schizophrenia, sensory gating, and nicotine receptors. Schizophr Bull 1998; 24: 189-202.
29. Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Rev Psychiatry 1996; 3: 241-253.
30. Deutsch SI, Rosse RB, Schwartz BL, Weizman A, Chilton M, Arnold DS, Mastropaolo J. Therapeutic implications of a selective α7 nicotinic receptor abnormality in schizophrenia. Isr J Psychiatry 2005; 42: 33-44.
31. Mike A, Castro NG, Albuquerque EX. Choline and acetylcholine have similar kinetic properties of activation and desensitization on the α7 nicotinic receptors in rat hippocampal neurons. Brain Res 2000; 882: 155-168.
32. Stevens KE, Freedman R, Collins AC, Hall M, Leonard S, Marks MJ, Rose GM. Genetic correlation of hippocampal auditory evoked response and α-bungarotoxin binding in inbred mouse strains. Neuropsychopharmacology 1996; 15: 152-162.
33. Stevens KE, Kem WR, Mahnir VM, Freedman R. Selective α7- nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology 1998; 136: 320-327.
34. Tamminga CA. Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 1998; 12: 21-36.
35. Olszewski RT, Wegorzewska MM, Monteiro AC, Krolikowski KA, Zhou J, Kozikowski AP, Long K, Mastropaolo J, Deutsch SI, Neale JH. PCP and MK-801 induced behaviors reduced by NAAG peptidase inhibition via metabotropic glutamate receptors. Biol Psychiatry 2008; 63: 86-91.
36. Deutsch SI, Schwartz BL, Rosse RB, Mastropaolo J, Marvel CL, Drapalski AL. Adjuvant topiramate administration: A pharmacologic strategy for addressing NMDA receptor hypofunction in schizophrenia. Clin Neuropharmacol 2003; 26: 199-206.
37. Gibbs JW, Sombati S, DeLorenzo RJ, Coulter DA. Cellular actions of topiramate: Blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 2000; 41: S10-S16.
38. Shank RP, Gardocki JF, Streeter AJ, Maranoff, BE. An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000; 41: S3-S9.
39. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 2000; 41: S17-S20.
40. Albuquerque EX, Alkondon M, Pereira EFR, Castro NG, Schrattenholz A, Barbosa CTF, Bonfante-Cabarcas R, Aracava Y, Eisenberg HM, Maelicke A. Properties of neuronal nicotinic acetylcholine receptors: Pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther 1997; 280: 1117-1136.
41. Leonard S, Gault J, Hopkins J, Logel J, Vianzon R, Short M, Drebing C, Berger R, Venn D, Sirota P, Zerbe G, Olincy A, Ross RG, Adler LE, Freedman R. Association of promoter variants in the α7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry 2002; 59: 1085-1096.
42. Rosse RB, Deutsch SI. Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin Neuropharmacol 2002; 25: 272-275.
43. Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signaling at hippocampal synapses. Nature 2001; 410: 588-592.